Given the significant role of ADAM9 as a protease with oncogenic effects in PCa progression 17,18, we identified polymorphisms in the promoter and intron regions of the ADAM9 gene that displayed different distributions in PCa patients with and those without BCR. This evidence concerns the gene ADAM9 and posterior cortical atrophy.